MX353382B - Moleculas de union polipeptido de larga duracion. - Google Patents
Moleculas de union polipeptido de larga duracion.Info
- Publication number
- MX353382B MX353382B MX2014010338A MX2014010338A MX353382B MX 353382 B MX353382 B MX 353382B MX 2014010338 A MX2014010338 A MX 2014010338A MX 2014010338 A MX2014010338 A MX 2014010338A MX 353382 B MX353382 B MX 353382B
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- domain
- molecule
- binding molecules
- long life
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una molécula de enlace o de unión que comprende al menos tres dominios comprendidos en al menos una cadena polipéptido, en donde el primer dominio de unión es un dominio de unión que es capaz de enlazar a una molécula de superficie celular en una célula objetivo, el segundo dominio de unión es un dominio de unión que es capaz de enlazar al complejo receptor CD3 de célula T y el tercer dominio es un dominio de unión que es capaz de enlazar albúmina de suero, en donde el tercer dominio se coloca en el extremo C del segundo dominio. Aún más, la invención proporciona una secuencia de ácido nucleico que codifica la molécula de enlace, un vector que comprende la secuencia de ácidos nucleicos y una célula huésped transformada o transfectada con el vector. Además, la invención proporciona un proceso para la producción de la molécula de enlace de la invención, un uso médico de la molécula de enlace y un equipo que comprende la molécula de enlace.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605681P | 2012-03-01 | 2012-03-01 | |
US201261606268P | 2012-03-02 | 2012-03-02 | |
PCT/EP2013/054223 WO2013128027A1 (en) | 2012-03-01 | 2013-03-01 | Long life polypeptide binding molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014010338A MX2014010338A (es) | 2014-11-14 |
MX353382B true MX353382B (es) | 2018-01-10 |
Family
ID=48128260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010338A MX353382B (es) | 2012-03-01 | 2013-03-01 | Moleculas de union polipeptido de larga duracion. |
Country Status (8)
Country | Link |
---|---|
US (3) | US20150037334A1 (es) |
EP (1) | EP2820047B1 (es) |
JP (4) | JP6407726B2 (es) |
AU (1) | AU2013224919B2 (es) |
CA (1) | CA2864177C (es) |
ES (1) | ES2680151T3 (es) |
MX (1) | MX353382B (es) |
WO (1) | WO2013128027A1 (es) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
US20140161800A1 (en) | 2011-04-22 | 2014-06-12 | John W. Blankenship | Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
ES2753950T3 (es) * | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Moléculas de unión monocatenarias que comprenden ABP del extremo N |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
ES2811923T3 (es) | 2013-12-17 | 2021-03-15 | Genentech Inc | Anticuerpos anti-CD3 y métodos de uso |
JP2017520575A (ja) | 2014-07-01 | 2017-07-27 | ファイザー・インク | 二重特異的ヘテロ二量体ダイアボディおよびその使用 |
WO2016016859A1 (en) * | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
CA2968987C (en) * | 2014-12-08 | 2022-05-10 | 1Globe Biomedical Co., Ltd. | Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof |
WO2016154047A2 (en) | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
JP2018520642A (ja) * | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
JP6841754B2 (ja) * | 2015-05-13 | 2021-03-10 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
EP4345112A3 (en) | 2015-05-13 | 2024-06-26 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
IL274151B (en) | 2015-05-21 | 2022-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
AU2016315656A1 (en) * | 2015-08-28 | 2018-02-01 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
SI3411404T1 (sl) | 2016-02-03 | 2023-01-31 | Amgen Research (Munich) Gmbh | Konstrukti bispecifičnih protiteles PSMA in CD3, ki aktivirajo T celico |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
CR20180420A (es) | 2016-02-03 | 2018-12-05 | Amgen Inc | Constructos de anticuerpo biespecíficos para bcma y cd3 que se ligan a células t |
JP7195927B2 (ja) * | 2016-03-08 | 2022-12-26 | 武田薬品工業株式会社 | 誘導性結合タンパク質及びその使用方法 |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
MX2018014227A (es) | 2016-05-20 | 2019-08-22 | Harpoon Therapeutics Inc | Proteinas de union de cadena unica de fragmento variable cd3. |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
WO2018075564A1 (en) * | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
CN109923128A (zh) | 2016-11-15 | 2019-06-21 | 基因泰克公司 | 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药 |
EA201991168A1 (ru) | 2016-11-23 | 2019-12-30 | Харпун Терапьютикс, Инк. | Белок, связывающий простатический специфический мембранный антиген |
KR20190087539A (ko) * | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
SG11201911527QA (en) * | 2017-06-05 | 2020-01-30 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa |
IL302614A (en) | 2017-09-08 | 2023-07-01 | Maverick Therapeutics Inc | Binding proteins are activated under limited conditions |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
CN111954677A (zh) | 2017-12-20 | 2020-11-17 | 莱蒂恩技术公司 | 用于用免疫治疗来治疗hiv/aids的组合物和方法 |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
BR112021007611A2 (pt) | 2018-10-23 | 2021-07-27 | Amgen Inc. | calibração automática e manutenção automática de modelos espectroscópicos raman para previsões em tempo real |
TW202043253A (zh) | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
CN114390938A (zh) | 2019-03-05 | 2022-04-22 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
EP4054590A1 (en) | 2019-11-04 | 2022-09-14 | Amgen Inc. | Methods for treating leukemia |
US20230071627A1 (en) | 2020-02-03 | 2023-03-09 | Amgen Inc. | Multivariate Bracketing Approach for Sterile Filter Validation |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
WO2022060878A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for treating prostate cancer |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
CN117043173A (zh) | 2021-03-10 | 2023-11-10 | 美国安进公司 | 重组蛋白的纯化方法 |
KR20230155490A (ko) | 2021-03-10 | 2023-11-10 | 암젠 인크 | 병렬 크로마토그래피 시스템 및 방법 |
WO2023056315A1 (en) * | 2021-09-29 | 2023-04-06 | Modex Therapeutics | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv |
TW202326113A (zh) | 2021-10-27 | 2023-07-01 | 美商安進公司 | 使用光譜學進行的基於深度學習的預測 |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
EP0623679B1 (en) | 1987-05-21 | 2003-06-25 | Micromet AG | Targeted multifunctional proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
IL138857A0 (en) | 1998-04-21 | 2001-10-31 | Micromet Ges For Biomedizinisc | Cd19xcd3 specific polypeptides and uses thereof |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
NZ546173A (en) | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
US8921528B2 (en) * | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
CA2633713A1 (en) * | 2005-12-21 | 2007-06-28 | Micromet Ag | Epha2 bite molecules and uses thereof |
PT2520590T (pt) * | 2007-04-03 | 2018-11-14 | Amgen Res Munich Gmbh | Domínio de ligação específico de espécies cruzadas |
RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
CA2738565C (en) * | 2008-10-01 | 2023-10-10 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
AU2009335798B2 (en) | 2008-12-19 | 2014-11-27 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
-
2013
- 2013-03-01 WO PCT/EP2013/054223 patent/WO2013128027A1/en active Application Filing
- 2013-03-01 JP JP2014559258A patent/JP6407726B2/ja active Active
- 2013-03-01 EP EP13716734.2A patent/EP2820047B1/en active Active
- 2013-03-01 AU AU2013224919A patent/AU2013224919B2/en active Active
- 2013-03-01 MX MX2014010338A patent/MX353382B/es active IP Right Grant
- 2013-03-01 CA CA2864177A patent/CA2864177C/en active Active
- 2013-03-01 US US14/381,902 patent/US20150037334A1/en not_active Abandoned
- 2013-03-01 ES ES13716734.2T patent/ES2680151T3/es active Active
-
2018
- 2018-04-05 JP JP2018072857A patent/JP6845177B2/ja active Active
- 2018-09-10 US US16/126,617 patent/US20190169295A1/en not_active Abandoned
-
2021
- 2021-02-25 JP JP2021028046A patent/JP2021087449A/ja active Pending
-
2022
- 2022-03-11 US US17/693,001 patent/US20230057728A1/en active Pending
-
2023
- 2023-02-13 JP JP2023019720A patent/JP2023053239A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6407726B2 (ja) | 2018-10-24 |
CA2864177C (en) | 2019-11-26 |
CA2864177A1 (en) | 2013-09-06 |
AU2013224919A1 (en) | 2014-08-28 |
JP2015509951A (ja) | 2015-04-02 |
WO2013128027A1 (en) | 2013-09-06 |
JP2021087449A (ja) | 2021-06-10 |
ES2680151T3 (es) | 2018-09-04 |
AU2013224919B2 (en) | 2017-12-07 |
US20190169295A1 (en) | 2019-06-06 |
JP2018138558A (ja) | 2018-09-06 |
MX2014010338A (es) | 2014-11-14 |
WO2013128027A9 (en) | 2015-12-17 |
US20150037334A1 (en) | 2015-02-05 |
EP2820047B1 (en) | 2018-04-25 |
JP2023053239A (ja) | 2023-04-12 |
US20230057728A1 (en) | 2023-02-23 |
EP2820047A1 (en) | 2015-01-07 |
JP6845177B2 (ja) | 2021-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX353382B (es) | Moleculas de union polipeptido de larga duracion. | |
PH12015501651A1 (en) | Antibody constructs for cdh19 and cd3 | |
PH12014501091A1 (en) | Binding molecules for bcma and cd3 | |
PH12015501672A1 (en) | Binding molecules for bcma and cd3 | |
GB2549632A8 (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
PH12018500216A1 (en) | Antibody constructs for cd70 and cd3 | |
MX2017001401A (es) | Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas. | |
GB201020995D0 (en) | Biological materials and uses thereof | |
MX2018001159A (es) | Constructos de anticuerpo para flt3 y cd3. | |
MX2017001403A (es) | Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido. | |
PH12015502278A1 (en) | Novel bispecific binding molecules with antitumoral activity | |
MX2014005546A (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
MX2014011066A (es) | Moleculas de union novedosas con actividad antitumoral. | |
EA201600338A1 (ru) | Биспецифическая связывающая молекула, связывающаяся с vegf и ang2 | |
CO6630173A2 (es) | Moléculas de unión a seroalbuminae | |
EA201492101A1 (ru) | Антитела против fcrn | |
GB201008682D0 (en) | Epitope tag for affinity based applications | |
AU2011353197A8 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
MX2016000393A (es) | Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana. | |
EA202092283A1 (ru) | Конструкции антител к cdh19 и cd3 | |
AR088884A1 (es) | Moleculas de union para bcma y cd3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |